Journal List > Korean J Schizophr Res > v.16(2) > 1057796

Jung, Cho, Yoon, Kang, Park, Lee, and Kim: Association between Antipsychotic-Related Restless Legs Syndrome and the RORA Gene Polymorphism in Schizophrenia

Abstract

Objectives

The previous studies have suggested genetic vulnerability to restless legs syndrome (RLS) development. The occurrence of antipsychotic-related RLS could also be attributable to differences in genetic susceptibility. This study aimed to investigate whether Retinoid-related orphan receptor A (RORA) gene polymorphism is associated with antipsychotic-related RLS in schizophrenia.

Methods

We assessed symptoms of antipsychotic-induced RLS in 190 Korean schizophrenic patients and divided the subjects into two groups according to the International Restless Legs Syndrome Study Group diagnostic criteria : 1) subjects that met all of the criteria (n=44) and 2) the remaining subjects who were not considered to be RLS patients (n=146). Single-nucleotide polymorphism in the RORA gene was genotyped by PCR in 190 individuals. The χ2-test was conducted to compare differences between two groups.

Results

The frequencies of genotype (χ2=0.066, p=0.968) of the RORA gene (rs11071547) did not differ significantly between schizophrenic patients with and without RLS. The difference of allele frequencies (χ2=0.008, p=0.927) of the RORA gene (rs 11071547) between the schizophrenic patients with and without RLS were not significant.

Conclusion

These results suggest that RORA gene polymorphism does not play a major role in susceptibility to antipsychotic-related RLS in schizophrenia.

REFERENCES

1). Karroum E, Konofal E, Arnulf I. Restless-legs syndrome. Rev Neurol (Paris). 2008; 164:701–721.
2). Rasmussen J, Videbech P. Restless legs syndrome and depression. Ugeskr Laeger. 2011; 173:2113–2117.
3). Kim WH, Kim BS, Kim SK, Chang SM, Lee DW, Cho MJ, et al. Restless legs syndrome in older people: a community-based study on its prevalence and association with major depressive disorder in older Korean adults. Int J Geriatr Psychiatry. 2012; 27:565–572.
crossref
4). Winter AC, Schurks M, Glynn RJ, Buring JE, Gaziano JM, Berger K, et al. Restless legs syndrome and risk of incident cardiovascular disease in women and men: prospective cohort study. BMJ Open. 2012; 2:e000866.
crossref
5). Cho YW, Shin WC, Yun CH, Hong SB, Kim JH, Allen RP, et al. Epidemiology of restless legs syndrome in Korean adults. Sleep. 2008; 31:219–223.
crossref
6). Trotti LM, Rye DB. Restless legs syndrome. Handb Clin Neurol. 2011; 100:661–673.
crossref
7). Giguere V, Tini M, Flock G, Ong E, Evans RM, Otulakowski G. Isoform-specific amino-terminal domains dictate DNA-binding properties of ROR alpha, a novel family of orphan hormone nuclear receptors. Genes Dev. 1994; 8:538–553.
8). Gachon F, Nagoshi E, Brown SA, Ripperger J, Schibler U. The mammalian circadian timing system: from gene expression to physiology. Chromosoma. 2004; 113:103–112.
crossref
9). DeBruyne JP, Weaver DR, Reppert SM. CLOCK and NPAS2 have overlapping roles in the suprachiasmatic circadian clock. Nat Neurosci. 2007; 10:543–545.
crossref
10). Guillaumond F, Dardente H, Giguere V, Cermakian N. Differential control of Bmal1 circadian transcription by REV-ERB and ROR nuclear receptors. J Biol Rhythms. 2005; 20:391–403.
crossref
11). Sato TK, Panda S, Miraglia LJ, Reyes TM, Rudic RD, McNamara P, et al. A functional genomics strategy reveals Rora as a component of the mammalian circadian clock. Neuron. 2004; 43:527–537.
crossref
12). Solt LA, Kojetin DJ, Burris TP. The REV-ERBs and RORs: molecular links between circadian rhythms and lipid homeostasis. Future Med Chem. 2011; 3:623–638.
crossref
13). Champion D, Pathirana S, Flynn C, Taylor A, Hopper JL, Berkovic SF, et al. Growing pains: Twin family study evidence for genetic susceptibility and a genetic relationship with restless legs syndrome. Eur J Pain. 2012.
14). Desautels A, Turecki G, Montplaisir J, Sequeira A, Verner A, Rouleau GA. Identification of a major susceptibility locus for restless legs syndrome on chromosome 12q. Am J Hum Genet. 2001; 69:1266–1270.
crossref
15). Bonati MT, Ferini-Strambi L, Aridon P, Oldani A, Zucconi M, Casari G. Autosomal dominant restless legs syndrome maps on chromosome 14q. Brain. 2003; 126:1485–1492.
crossref
16). Chen S, Ondo WG, Rao S, Li L, Chen Q, Wang Q. Genomewide linkage scan identifies a novel susceptibility locus for restless legs syndrome on chromosome 9p. Am J Hum Genet. 2004; 74:876–885.
crossref
17). Levchenko A, Provost S, Montplaisir JY, Xiong L, St-Onge J, Thi-bodeau P, et al. A novel autosomal dominant restless legs syndrome locus maps to chromosome 20p13. Neurology. 2006; 67:900–901.
crossref
18). Pichler I, Marroni F, Volpato CB, Gusella JF, Klein C, Casari G, et al. Linkage analysis identifies a novel locus for restless legs syndrome on chromosome 2q in a South Tyrolean population isolate. Am J Hum Genet. 2006; 79:716–723.
crossref
19). Kemlink D, Plazzi G, Vetrugno R, Provini F, Polo O, Stiasny-Kol-ster K, et al. Suggestive evidence for linkage for restless legs syndrome on chromosome 19p13. Neurogenetics. 2008; 9:75–82.
crossref
20). Levchenko A, Montplaisir JY, Asselin G, Provost S, Girard SL, Xiong L, et al. Autosomal-dominant locus for Restless Legs Syndrome in French-Canadians on chromosome 16p12.1. Mov Disord. 2009; 24:40–50.
crossref
21). Stefansson H, Rye DB, Hicks A, Petursson H, Ingason A, Thorgeirs-son TE, et al. A genetic risk factor for periodic limb movements in sleep. N Engl J Med. 2007; 357:639–647.
crossref
22). Winkelmann J, Schormair B, Lichtner P, Ripke S, Xiong L, Jalilza-deh S, et al. Genomewide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet. 2007; 39:1000–1006.
crossref
23). Schormair B, Kemlink D, Roeske D, Eckstein G, Xiong L, Lichtner P, et al. PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome. Nat Genet. 2008; 40:946–948.
crossref
24). Kang SG, Lee HJ, Jung SW, Cho SN, Han C, Kim YK, et al. Characteristics and clinical correlates of restless legs syndrome in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2007; 31:1078–1083.
crossref
25). Kang SG, Lee HJ, Kim L. Restless legs syndrome and periodic limb movements during sleep probably associated with olanzapine. J Psychopharmacol. 2009; 23:597–601.
crossref
26). Kang SG, Lee HJ, Choi JE, Park JH, Lee SS, Han CS, et al. Possible association between G-protein β3 subunit C825T polymorphism and antipsychotic-induced restless legs syndrome in schizophrenia. Acta Neuropsychiatrica. 2007; 19:351–356.
crossref
27). Kang SG, Lee HJ, Choi JE, Park YM, Park JH, Han C, et al. Association study between antipsychotics- induced restless legs syndrome and polymorphisms of dopamine D1, D2, D3, and D4 receptor genes in schizophrenia. Neuropsychobiology. 2008; 57:49–54.
crossref
28). Cho CH, Kang SG, Choi JE, Park YM, Lee HJ, Kim L. Association between Antipsychotics-Induced Restless Legs Syndrome and Tyrosine Hydroxylase Gene Polymorphism. Psychiatry Investig. 2009; 6:211–215.
crossref
29). Kang SG, Park YM, Choi JE, Lim SW, Lee HJ, Lee SH, et al. Association study between antipsychotic-induced restless legs syndrome and polymorphisms of monoamine oxidase genes in schizophrenia. Hum Psychopharmacol. 2010; 25:397–403.
crossref
30). Kang SG, Lee HJ, Park YM, Yang HJ, Song HM, Lee YJ, et al. The BTBD9 gene may be associated with antipsychotic-induced restless legs syndrome in schizophrenia. Hum Psychopharmacol. 2013; 28:117–123.
31). Walters AS, LeBrocq C, Dhar A, Hening W, Rosen R, Allen RP, et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med. 2003; 4:121–132.
32). Soldatos CR, Dikeos DG, Paparrigopoulos TJ. The diagnostic validity of the Athens Insomnia Scale. J Psychosom Res. 2003; 55:263–267.
crossref
33). Lykke J, Hesse M, Austin SF, Oestrich I. Validity of the BPRS, the BDI and the BAI in dual diagnosis patients. Addict Behav. 2008; 33:292–300.
crossref
34). Michaud M, Dumont M, Selmaoui B, Paquet J, Fantini ML, Montplaisir J. Circadian rhythm of restless legs syndrome: relationship with biological markers. Ann Neurol. 2004; 55:372–380.
crossref
35). Odrcich M, Bailey JM, Cahill CM, Gilron I. Chronobiological characteristics of painful diabetic neuropathy and postherpetic neuralgia: diurnal pain variation and effects of analgesic therapy. Pain. 2006; 120:207–212.
crossref
36). Baier PC, Trenkwalder C. Circadian variation in restless legs syndrome. Sleep Med. 2007; 8:645–650.
crossref
37). Akashi M, Takumi T. The orphan nuclear receptor RORalpha reg-ulates circadian transcription of the mammalian core-clock Bmal1. Nat Struct Mol Biol. 2005; 12:441–448.
38). Kamphuis W, Cailotto C, Dijk F, Bergen A, Buijs RM. Circadian expression of clock genes and clock-controlled genes in the rat retina. Biochem Biophys Res Commun. 2005; 330:18–26.
crossref
39). Tosini G, Davidson AJ, Fukuhara C, Kasamatsu M, Castanon-Cervantes O. Localization of a circadian clock in mammalian photore-ceptors. FASEB J. 2007; 21:3866–3871.
crossref
40). Yang X, Downes M, Yu RT, Bookout AL, He W, Straume M, et al. Nuclear receptor expression links the circadian clock to metabolism. Cell. 2006; 126:801–810.
crossref
41). Ueda HR, Chen W, Adachi A, Wakamatsu H, Hayashi S, Takasugi T, et al. A transcription factor response element for gene expression during circadian night. Nature. 2002; 418:534–539.
crossref
42). Ino H. Immunohistochemical characterization of the orphan nuclear receptor ROR alpha in the mouse nervous system. J Histochem Cytochem. 2004; 52:311–323.
43). Boukhtouche F, Vodjdani G, Jarvis CI, Bakouche J, Staels B, Mallet J, et al. Human retinoic acid receptor-related orphan receptor al-pha1 overexpression protects neurones against oxidative stress-induced apoptosis. J Neurochem. 2006; 96:1778–1789.
44). Frederic F, Chianale C, Oliver C, Mariani J. Enhanced endocrine response to novel environment stress and lack of corticosterone circadian rhythm in staggerer (Rora sg/sg) mutant mice. J Neurosci Res. 2006; 83:1525–1532.
45). Jarvis CI, Staels B, Brugg B, Lemaigre-Dubreuil Y, Tedgui A, Mariani J. Age-related phenotypes in the staggerer mouse expand the RORalpha nuclear receptor's role beyond the cerebellum. Mol Cell Endocrinol. 2002; 186:1–5.
46). Dzhagalov I, Giguere V, He YW. Lymphocyte development and function in the absence of retinoic acid-related orphan receptor alpha. J Immunol. 2004; 173:2952–2959.
47). Kopmels B, Mariani J, Delhaye-Bouchaud N, Audibert F, Fradelizi D, Wollman EE. Evidence for a hyperexcitability state of staggerer mutant mice macrophages. J Neurochem. 1992; 58:192–199.
crossref
48). Kripke DF, Nievergelt CM, Tranah GJ, Murray SS, Rex KM, Grizas AP, et al. FMR1, circadian genes and depression: suggestive associations or false discovery? J Circadian Rhythms. 2013; 11:3.
crossref
49). Lavebratt C, Sjoholm LK, Partonen T, Schalling M, Forsell Y. PER2 variantion is associated with depression vulnerability. Am J Med Genet B Neuropsychiatr Genet. 2010; 153:570–581.
crossref
50). Utge SJ, Soronen P, Loukola A, Kronholm E, Ollila HM, Pirkola S, et al. Systematic analysis of circadian genes in a population-based sample reveals association of TIMELESS with depression and sleep disturbance. PLoS One. 2010; 5:e9259.
crossref
51). Kripke DF, Shadan FF, Dawson A, Cronin JW, Jamil SM, Grizas AP, et al. Genotyping sleep disorders patients. Psychiatry Investig. 2010; 7:36–42.
crossref

Table 1.
Comparison of the genotype and allele frequencies of the RORA (rs11071547) between schizophrenic patients with and without RLS
Genotype Allele frequencies
CC CT TT C T
Schizophrenia with RLS (n=44) 6 (13.6%) 18 (40.9%) 20 (45.5%) χ2=0.066 30 (34%) 58 (66%) χ2=0.008
Schizophrenia without RLS (n=146) 18 (12.3%) 62 (42.5%) 66 (45.2%) p=0.968 98 (34%) 194 (66%) p=0.927

RORA : Retinoid-related orphan receptor, RLS : Restless legs syndrome

TOOLS
Similar articles